Bolt Biotherapeutics’ (BOLT) Neutral Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their neutral rating on shares of Bolt Biotherapeutics (NASDAQ:BOLT) in a research note published on Tuesday morning,Benzinga reports.

Separately, Stifel Nicolaus cut their price objective on Bolt Biotherapeutics from $1.50 to $1.25 and set a “hold” rating on the stock in a research report on Tuesday. Five investment analysts have rated the stock with a hold rating, According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $1.13.

Bolt Biotherapeutics Stock Performance

Shares of BOLT stock opened at $0.42 on Tuesday. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.16 and a quick ratio of 3.16. The firm has a 50-day moving average of $0.47 and a 200-day moving average of $0.56. Bolt Biotherapeutics has a one year low of $0.38 and a one year high of $1.56. The company has a market cap of $16.07 million, a P/E ratio of -0.25 and a beta of 0.94.

Bolt Biotherapeutics (NASDAQ:BOLT) last posted its quarterly earnings data on Monday, March 24th. The company reported ($0.38) EPS for the quarter, meeting the consensus estimate of ($0.38). Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 69.46%. The firm had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.79 million. Equities research analysts forecast that Bolt Biotherapeutics will post -1.61 EPS for the current fiscal year.

Institutional Investors Weigh In On Bolt Biotherapeutics

A number of hedge funds have recently modified their holdings of the stock. FMR LLC increased its position in Bolt Biotherapeutics by 33.2% in the third quarter. FMR LLC now owns 115,386 shares of the company’s stock worth $75,000 after buying an additional 28,773 shares during the last quarter. Citadel Advisors LLC bought a new position in shares of Bolt Biotherapeutics during the 4th quarter worth $42,000. Millennium Management LLC purchased a new stake in Bolt Biotherapeutics in the 4th quarter worth about $25,000. Squarepoint Ops LLC bought a new stake in Bolt Biotherapeutics in the 4th quarter valued at about $26,000. Finally, Velan Capital Investment Management LP purchased a new stake in Bolt Biotherapeutics during the fourth quarter valued at about $27,000. Institutional investors own 86.70% of the company’s stock.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.